Cardiff Oncology (CRDF) has completed enrollment for the phase 2 trial assessing a combination of its onvansertib drug candidate with the standard of care in patients with first-line, RAS-mutated metastatic colorectal cancer.
Patients across 41 clinical sites in the US are randomized into either 20- or 30-milligram onvansertib plus standard of care, or standard of care alone. The study has a primary endpoint of an objective response rate and secondary endpoints including progression-free survival, duration of response and safety, the company said.
Cardiff said it expects to report additional clinical data from the mid-stage trial later during the current quarter.
Cardiff shares recently were fractionally higher during Tuesday's after-hours session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.